Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line Treatment

News   Nov 22, 2017 | Original story from The Institute of Cancer Research

 
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line Treatment

Credit: The Institute of Cancer Research

 
 
 

RELATED ARTICLES

New Drug Successfully Treats Huntington Patients

News

The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial, and successfully lowered the level of the harmful huntingtin protein in the nervous system.

READ MORE

Severity of Autoimmune Disease Influenced by Time of Day

News

Insights into how the body clock and time of day influence immune responses are revealed today. Understanding the effect of the interplay between 24-hour day-night cycles and the immune system may help inform drug-targeting strategies to alleviate autoimmune disease.

READ MORE

Agent Reverses Resistance to Targeted Drug in Some Leukemias

News

After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.

READ MORE

 

Comments | 1 ADD COMMENT

Leonard Adams | Dec 08, 2017

I had no idea about this. My urologist is very opposed to drugs that have not undergone through rigorous clinical trials, I have BPH and he prescribed me alpharise health. It has been a very effective cure for my bph symptoms.


Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE